Home » Stocks » CryoLife

CryoLife, Inc. (CRY)

Stock Price: $21.22 USD 0.36 (1.73%)
Updated Aug 13, 2020 3:17 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 803.35M
Revenue (ttm) 257.78M
Net Income (ttm) -11.17M
Shares Out 37.86M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE 714.29
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $21.22
Previous Close $20.86
Change ($) 0.36
Change (%) 1.73%
Day's Open 20.70
Day's Range 20.56 - 21.31
Day's Volume 56,260
52-Week Range 12.63 - 31.77

More Stats

Market Cap 803.35M
Enterprise Value 988.63M
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 37.86M
Float 36.21M
EPS (basic) -0.29
EPS (diluted) -0.30
FCF / Share 0.12
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 0.58%
Payout Ratio n/a
Shares Short 4.09M
Short Ratio 12.39
Short % of Float 13.30%
Beta 1.35
PE Ratio n/a
Forward PE 714.29
P/FCF Ratio 172.54
PS Ratio 3.12
PB Ratio 2.69
Revenue 257.78M
Operating Income 5.23M
Net Income -11.17M
Free Cash Flow 4.66M
Net Cash -185.29M
Net Cash / Share -4.89
Gross Margin 71.00%
Operating Margin 2.03%
Profit Margin -4.30%
FCF Margin 1.81%
ROA 0.51%
ROE -3.86%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$26.30*
(23.94% upside)
Low
21.0
Current: $21.22
High
29.5
Target: 26.30
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue276263190180146145141132120117
Revenue Growth5.09%38.55%5.17%23.63%0.87%2.75%6.87%10.11%2.56%-
Gross Profit18317312911990.7291.2990.3985.0275.8468.37
Operating Income17.049.317.9713.915.358.8413.8212.6111.649.87
Net Income1.72-2.843.7010.784.017.3216.177.957.373.94
Shares Outstanding37.1236.4133.0131.8627.7427.3826.8926.9727.4427.99
Earnings Per Share0.05-0.080.110.320.140.250.570.280.260.14
EPS Growth---65.63%128.57%-44%-56.14%103.57%7.69%85.71%-
Dividend Per Share----0.120.120.120.05--
Dividend Growth----0%2.56%134%---
Operating Cash Flow15.839.8810.8019.7211.448.1216.7718.9916.7520.84
Capital Expenditures-8.07-5.79-6.63-6.20-3.49-4.31-4.34-3.07-2.54-2.12
Free Cash Flow7.764.104.1713.527.953.8112.4315.9214.2118.72
Cash & Equivalents34.2942.2440.7557.3443.4239.2642.9918.3322.0240.81
Total Debt23922422671.59------
Net Cash / Debt-205-181-186-14.2443.4239.2642.9918.3322.0240.81
Assets606571590316181176175157148137
Liabilities32029631310725.9327.4729.9429.0426.3323.50
Book Value286275277209155149145128122114
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CryoLife, Inc.
Country United States
Employees 1,200
CEO James Patrick Mackin

Stock Information

Ticker Symbol CRY
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Medical Devices
Unique Identifier NYSE: CRY
IPO Date February 11, 1993

Description

CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products, a range of stent graft systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G, a stent graft system for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers vascular preservation services; synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products, such as YAG laser consoles, related service and maintenance, and single-use, fiber-optic handpieces; and CryoVein femoral vein and CryoArtery femoral artery vascular preservation services for vascular access. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.